Study wrapper · #929
Triple Hormone Receptor Agonism: The Role of Retatrutide in Addressing Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Comprehensive Review.
Pillai AA, Godin SL, Frishman WH, et al. Cardiology in review. 2026.
DOI: 10.1097/crd.0000000000001310PubMed: 42108533
Editor's note
This review consolidates phase 2 data with retatrutide as its central subject, making it a useful synthesis even though reviews sit below trials in the evidence hierarchy. It reports large reductions in weight, HbA1c, hepatic fat, and blood pressure alongside a dose-dependent increase in heart rate that clinicians must monitor. Figures come from phase 2 studies and await phase 3 confirmation.
Plain-language abstract
A comprehensive review summarizing phase 2 evidence that retatrutide is associated with substantial weight loss, improved blood sugar, reduced liver fat, and lower blood pressure, while noting a dose-dependent heart-rate effect.
Related coverage
Mixed
Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application.
Journal of chromatography. An=——2026
Supported
Comparative effects of semaglutide tirzepatide and retatrutide on renal fibrosis in UUO and aged mice.
iSciencen=——2026
Supported
CARDIOVASCULAR EFFECTS OF INCRETIN RECEPTOR AGONISTS: BEYOND GLYCEMIC CONTROL.
Canadian journal of physiology and pharmacologyn=——2026